Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Metrics to compare | FOLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFOLDPeersSector | |
---|---|---|---|---|
P/E Ratio | −27.9x | −3.3x | −0.7x | |
PEG Ratio | −0.66 | −0.07 | 0.00 | |
Price / Book | 16.4x | 2.4x | 2.6x | |
Price / LTM Sales | 5.9x | 9.9x | 3.1x | |
Upside (Analyst Target) | 74.0% | 136.1% | 47.6% | |
Fair Value Upside | Unlock | 14.7% | 7.7% | Unlock |